Molecular Imaging from Basic Research to Clinical Application
update：2020-06-16
Features
Molecular Imaging and its Application to Drug Development: Positron emission tomography (PET) comprises the administration of carbon-11- or fluorine-18-labeled tracers to human subjects in order to describe the concentration-time profile in body tissues targeted for treatment. As PET involves the administration of only microgram amounts of unlabeled drug, the potential risk to human subjects is very limited. Consequently, required preclinical safety testing is reduced as compared to conventional human studies.Targeted Application(s)/Industry
PET molecular imaging studies are gaining increasing importance in clinical drug research, as they have the potential to shorten time-lines and cut costs along the critical path of drug development. We have developed several PET tracers for molecular imaging such as amyloid imaging and central nervous system drug research at Tohoku University, Japan. We will present the recent progress and strategy of "PET molecular imaging" in order to accelerate drug development.Researchers
Department of Pharmacology, Graduate School of Medicine, and Cyclotron and Radioisotope Center
YANAI Kazuhiko
, Professor
MD., PhD
Keywords
Related Information
Prev
List
Next